Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration

• David G. Parr ^[3] ; Joanna Chorostowska-Wynimko ^[4] ; Angelo Corsico ^[5] ; Cristina Esquinas ^[6] ; Gerard N. McElvaney ^[7] ; Annelot D. Sark ^[1] ; Maria Sucena ^[8] ; Hanan Tanash ^[9] ; Alice M. Turner ^[2] ; Marc Miravitlles ^[6]
  1. [1] Leiden University Medical Center

     Leiden University Medical Center

     Países Bajos

     
  2. [2] University of Birmingham

     University of Birmingham

     Reino Unido

     
  3. [3] Department of Respiratory Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
  4. [4] Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Disease, Warsaw, Poland
  5. [5] Respiratory Diseases Division, IRCCS Policlinico San Matteo Foundation and University of Pavia, Italy
  6. [6] Servicio de Neumología, Hospital Universitari Vall d’Hebron/Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, España
  7. [7] Irish Centre for Genetic Lung Disease, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland
  8. [8] Pulmonology Department, Centro Hospitalar Universitário do Porto, Porto, Portugal
  9. [9] Department of Respiratory Medicine and Allergology, Skåne University Hospital, Lund University, Sweden

  Mostrar afiliaciones +
• Localización: Archivos de bronconeumología: Organo oficial de la Sociedad Española de Neumología y Cirugía Torácica SEPAR y la Asociación Latinoamericana de Tórax ( ALAT ), ISSN 0300-2896, Vol. 58, Nº. 12 (December), 2022, págs. 840-842
• Idioma: inglés
• Texto completo no disponible (Saber más ...)